Opportunity
Simpler Grants.gov #RFA-DK-26-302
NIH Kidney Precision Medicine Project: Tissue Interrogation Sites Funding Opportunity
Buyer
National Institutes of Health
Posted
September 10, 2025
Respond By
October 05, 2026
Identifier
RFA-DK-26-302
NAICS
541715
The National Institutes of Health (NIH) is seeking applications for the Kidney Precision Medicine Project (KPMP) Tissue Interrogation Sites (TIS) to advance kidney disease research. - Government Buyer: - National Institutes of Health (NIH) - Project Scope: - Establish Tissue Interrogation Sites to analyze human kidney tissue - Collaborate with Recruitment Sites, the Kidney Tissue Atlas Coordinating Center, and the Central Hub - Obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) or chronic kidney disease (CKD) - Create a comprehensive Kidney Tissue Atlas - Define disease subgroups and identify critical cells, interstitial components, pathways, and therapeutic targets - Funding Details: - Estimated program funding: $6,000,000 - Approximately seven awards expected - No cost sharing or matching required - Eligibility: - Open to nonprofits, government entities, educational institutions, businesses, and other organizations, including federal agencies and foreign institutions - Products/Services Requested: - No specific OEMs, vendors, or commercial products identified - Primary requirement is for advanced tissue analysis and research services - Unique Requirements: - Emphasis on collaboration across multiple research sites - Focus on generating actionable insights for kidney disease therapies
Description
This Notice of Funding Opportunity (NOFO) requests applications for the Kidney Precision Medicine Project (KPMP) - Tissue Interrogation Sites (TIS) to analyze human kidney tissue. The TIS will collaborate with Recruitment Sites, Kidney Tissue Atlas Coordinating Center, and Central Hub to obtain and evaluate kidney biopsies from participants with acute kidney injury or chronic kidney disease. The project aims to create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies. The funding instrument type is a cooperative agreement with no cost sharing or matching requirement.